Skip to main navigation
menu

Site - Top Menu

  • About
  • Our Science
  • Neurotology
  • Pipeline
  • Patient Resources
  • Investors
    • « Back
    • Overview
    • News & Events
      • Press Releases
      • Presentations
      • Events
    • Financial Information
      • SEC Filings
      • Annual Reports & Proxies
    • Investor Resources
      • Investor FAQs
      • E-mail Alerts
      • Contact Us
    • Corporate Governance
    • Stock Information and Analyst Coverage

News & Events

Press Releases Presentations Events

Press releases

Press releases

  • Apr 07, 2021 Otonomy Announces Pricing of $30.1 Million Public Offering
  • Apr 07, 2021 Otonomy Announces Proposed Public Offering
  • Apr 06, 2021 Otonomy to Present at the Needham Virtual Healthcare Conference
  • Apr 05, 2021 Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
  • Mar 25, 2021 Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
  • Feb 25, 2021 Otonomy to Participate in Three Upcoming Investor Conferences
  • Feb 22, 2021 Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
  • Feb 17, 2021 Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
  • Feb 11, 2021 Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
  • Feb 04, 2021 Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
X
  • Facebook
  • LinkedIn
  • Google
  • Careers
  • Contact
  • Terms of Use
  • Privacy Policy
©2021 Otonomy